Pharmacokinetics and pharmacodynamics of cannabis‐based medicine in a patient population included in a randomized, placebo‐controlled, clinical trial
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13685 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Julie Schjødtz Hansen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Cannabis, Cannabidiol, Multiple Sclerosis, Neuralgia. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Information on the pharmacokinetics (PK) and pharmacodynamics (PD) of orally administered cannabis‐based medicine (CBM) in capsule formulation in patient populations is sparse. In this exploratory study, we aimed to evaluate the PK and PD in a probable steady state of CBM in neuropathic pain and spasticity in a population of patients with multiple sclerosis (MS). Of 134 patients participating in a randomized, double‐blinded, placebo‐controlled, trial, 23 patients with MS (17 female) mean age 52 years (range 21–67) were enrolled in this substudy. They received oral capsules containing Δ 9 ‐tetrahydrocannabinol (THC, n = 4), cannabidiol (CBD, n = 6), a combination (THC&CBD, n = 4), or placebo ( n = 9). Maximum doses were 22.5 mg (THC) and 45 mg (CBD) a day divided into three administrations. PD parameters were evaluated for pain and spasticity. Blood samples were analyzed using an ultra‐high‐performance liquid chromatography–tandem mass spectrometer after protein precipitation and phospholipid removal. PK parameters were estimated using computerized modeling. The variation in daily dose and PK between individuals was considerable in a steady state, yet comparable with previous reports from healthy controls. Based on a simulation of the best model, the estimated PK parameters (mean) for THC (5 mg) were C max 1.21 ng/mL, T max 2.68 h, and half‐life 2.75 h, and for CBD (10 mg) were C max 2.67 ng/mL, T max 0.10 h, and half‐life 4.95 h, respectively. No effect was found on the PD parameters, but the placebo response was considerable. More immediate adverse events were registered in the active treatment groups compared with the placebo group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
- Section for Drug Abuse Research, Department of Forensic Sciences, Division of Laboratory Medicine, Oslo University Hospital, Oslo, Norway.
- Department of Forensic Medicine, Aarhus University, Aarhus, Denmark.
- Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark.
- Department of Biomedicine, Aarhus University, Aarhus, Denmark.
ORCID-Profile: Julie Schjødtz Hansen, Finn Sellebjerg, Peter Vestergaard Rasmussen
Zitieren
APA
Hansen, J. S., Boix, F., Hasselstrøm, J. B., Sørensen, L. K., Kjolby, M., Gustavsen, S., Hansen, R. M., Petersen, T., Sellebjerg, F., Kasch, H., Rasmussen, P. V., Finnerup, N. B., Saedder, E. A., & Svendsen, K. B. (2024). Pharmacokinetics and pharmacodynamics of cannabis‐based medicine in a patient population included in a randomized, placebo‐controlled, clinical trial. Clinical and Translational Science. https://doi.org/10.1111/cts.13685
Vancouver
Hansen JS, Boix F, Hasselstrøm JB, Sørensen LK, Kjolby M, Gustavsen S, et al. Pharmacokinetics and pharmacodynamics of cannabis‐based medicine in a patient population included in a randomized, placebo‐controlled, clinical trial. Clinical and Translational Science. 2024. doi:10.1111/cts.13685
BibTeX
@article{Hansen2024,
author = {Hansen, Julie Schjødtz and Boix, Fernando and Hasselstrøm, Jørgen Bo and Sørensen, Lambert Kristiansen and Kjolby, Mads and Gustavsen, Stefan and Hansen, Rikke Middelhede and Petersen, Thor and Sellebjerg, Finn and Kasch, Helge and Rasmussen, Peter Vestergaard and Finnerup, Nanna Brix and Saedder, Eva Aggerholm and Svendsen, Kristina Bacher},
title = {Pharmacokinetics and pharmacodynamics of cannabis‐based medicine in a patient population included in a randomized, placebo‐controlled, clinical trial},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13685}
}
EUVIMED